Sanchine三精品牌怎么样 申请店铺

我要投票 Sanchine三精在补钙行业中的票数:146 更新时间:2025-01-22
Sanchine三精是哪个国家的品牌?「Sanchine三精」是 哈药集团三精制药有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人芦传有在2015期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
Sanchine三精怎么样

三精制药始建于1950年,初期以生产肌肉和静脉水针剂为主,是黑龙江省最早的专业化生产水针剂和国内最早引进国外水针剂一连机生产设备的企业,是最早通过国家GMP认证的医药企业之一。公司现总占地面积110万平方米,员工总数近6000人,是以OTC产品、处方药与保健食品为主、医药原料和制剂并重的综合性制药企业。2004年,“三精”品牌被国家工商总局认定为“驰名保护”。2011年5月13日,“三精”品牌在“2011中国最有价值品牌评价”中,经权威机构认定,品牌价值为68.93亿元人民币。

目前,三精制药拥有下属子公司15家,其中工业子公司8家、商业子公司5家、其他相关产业子公司2家。截至目前,公司口服液、口服溶液剂、小容量注射剂(非最终灭菌)、冻干粉针剂、片剂、粉针剂、胶囊剂、颗粒剂、合剂、糖浆剂、洗剂、茶剂、散剂13个剂型及无菌原料药(磷霉素钠、炎琥宁)、原料药(拉西地平、盐酸罗沙替丁醋酸酯)均通过2010版GMP认证。其中,口服液剂型产品年生产能力达16亿支。公司主导产品包括葡萄糖酸钙口服溶液、葡萄糖酸锌口服液、双黄连口服液、司乐平片等。近年来,通过药品、保健品的新产品立项研发,不断完善产品线,丰富产品阵容。

六十余年的制药经验,先进的技术设备,一流的管理手段,完善的科研开发体系,使“三精”牌在国内外丰享盛誉。三精一直将产品和服务视为核心竞争力,同时高度重视产品的研发,2004年建成较具规模的研发中心,已成为黑龙江省药物制剂工程技术研究中心、黑龙江省西药制剂重点实验室,承担“十一五”“重大新药创制”科技重大专项——“新型口服缓控释制剂及工艺技术平台”课题和“十二五”“重大新药创制”科技重大专项——“抗阿尔茨海默病药重酒石酸卡巴拉汀及其胶囊的研究开发”课题。2008年,公司成为“国家首批创新型企业”,2012年入选国家火炬计划重点高新技术企业。公司还先后荣获了全国质量管理先进企业、全国守合同重信用企业、全国医药系统优秀企业、全国“五·一劳动奖状”先进集体、“全国企业文化优秀成果奖”、“全国医药行业药品质量诚信建设示范企业”、“21315国际质量信用AAA++级”、“中国优秀诚信企业”、“中国化学制药行业工业企业综合实力百强”企业、黑龙江省“科技创新优秀企业奖”等荣誉称号。

Sanjing pharmaceutical was founded in 1950. At the early stage, it mainly produces muscle and intravenous water injection. It is the first professional enterprise in Heilongjiang Province to produce water injection and the first enterprise in China to introduce foreign water injection production equipment. It is also one of the first pharmaceutical enterprises to pass the national GMP certification. The company now covers an area of 1.1 million square meters and employs nearly 6000 people. It is a comprehensive pharmaceutical enterprise focusing on OTC products, prescription drugs and health food, with equal emphasis on pharmaceutical raw materials and preparations. In 2004, "three fine" brand was recognized as "well-known protection" by the State Administration for Industry and commerce. On May 13, 2011, in the "2011 China's most valuable brand evaluation", the brand value of "three fine" was recognized by the authority as RMB 6.893 billion. At present, Sanjing pharmaceutical has 15 subsidiaries, including 8 Industrial subsidiaries, 5 Commercial subsidiaries and 2 other related industrial subsidiaries. Up to now, 13 dosage forms of the company's oral liquid, oral solution, small volume injection (non final sterilization), freeze-dried powder injection, tablet, powder injection, capsule, granule, mixture, syrup, lotion, tea, powder, sterile API (fosfomycin sodium, Yanhuning), API (lacidipine, rosattidine hydrochloride acetate) have passed GMP certification of 2010 version. Among them, the annual production capacity of oral liquid dosage products reached 1.6 billion. The company's leading products include calcium gluconate oral solution, zinc gluconate oral solution, Shuanghuanglian oral solution, and silepin tablets. In recent years, through the research and development of new products of drugs and health products, the product line has been continuously improved and the product lineup has been enriched. With more than 60 years of pharmaceutical experience, advanced technology and equipment, first-class management means, and perfect scientific research and development system, the "three refined" brand enjoys a good reputation at home and abroad. Sanjing has always regarded products and services as its core competitiveness, and attached great importance to product research and development. In 2004, it established a relatively large-scale research and development center, which has become Heilongjiang pharmaceutical engineering and technology research center and Heilongjiang western pharmaceutical Key Laboratory, undertaking the major science and technology project of "11th Five Year plan" and "major new drug creation" -- new oral sustained and controlled release preparations and technology "Platform" project and "12th Five Year Plan" science and technology major project of "major new drug creation" - research and development of anti Alzheimer's disease drug kabalatin tartrate and its capsule ". In 2008, the company became "the first batch of national innovative enterprises", and in 2012, it was selected as a key high-tech enterprise in the national torch plan. The company has also won the national advanced quality management enterprise, the national contract abiding and trustworthy enterprise, the national excellent pharmaceutical system enterprise, the national advanced collective of "May 1st Labor Award", "national enterprise culture excellent achievement award", "national pharmaceutical industry pharmaceutical quality and integrity construction demonstration enterprise", "21315 International quality and credit AAA + + level", "China excellent and integrity enterprise" "Top 100 enterprises with comprehensive strength in China's chemical and pharmaceutical industry" and "science and technology innovation excellent enterprise award" of Heilongjiang Province, etc.

本文链接: https://brand.waitui.com/41c6b1011.html 联系电话:0451-86627550

千城特选小程序码

7×24h 快讯

中科飞测:向特定对象发行A股股票申请获上交所受理

36氪获悉,中科飞测公告,公司于2025年1月22日收到上交所关于受理公司科创板上市公司发行证券申请的通知。上交所对公司报送的募集说明书及相关申请文件进行了核对,认为申请文件齐备,符合法定形式,决定予以受理并依法进行审核。公司本次向特定对象发行A股股票事项尚需通过上交所审核,并获得中国证监会同意注册的决定后方可实施。上述事项最终能否通过上交所审核,并获得中国证监会同意注册的决定及其时间尚存在不确定性。

2小时前

*ST鹏博:公司股票可能被终止上市

36氪获悉,*ST鹏博公告,因中喜会计师事务所对公司出具了无法表示意见的《2023年度审计报告》,公司股票被实施退市风险警示。若公司2024年度财务会计报告被出具保留意见、无法表示意见或否定意见的审计报告以及财务报告内部控制被出具无法表示意见或者否定意见的审计报告,公司股票将被上海证券交易所决定终止上市。公司预计2024年年度归属于母公司所有者的净利润约为-7.75亿元,扣除非经常性损益后的净利润约为-7.36亿元。预计2024年年度实现营业收入约为18.87亿元。预计2024年年末归属于母公司净资产约为1.9亿元。

2小时前

摩根大通美国国债客户多头占比创2023年以来新高

摩根大通美国国债客户调查显示,截至1月21日当周,多头占比上升2个百分点,至2023年12月4日以来的最高水平。净多头创同日以来新高,空头占比下降4个百分点,中性上升2个百分点。(界面)

2小时前

美股大型科技股盘前多数上涨,奈飞涨超14%

36氪获悉,美股大型科技股盘前多数上涨,截至发稿,奈飞涨超14%,英伟达涨超3%,Meta、微软涨超1%,亚马逊涨0.72%,谷歌涨0.01%,特斯拉跌超1%,苹果跌0.24%。

2小时前

热门中概股美股盘前多数下跌,理想汽车跌超2%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,理想汽车跌超2%,哔哩哔哩、腾讯音乐跌超1%,小鹏汽车跌0.93%,百度跌0.68%,阿里巴巴跌0.18%,拼多多跌0.12%,京东涨超1%,蔚来涨0.48%。

2小时前

本页详细列出关于童年时光ChildLife的品牌信息,含品牌所属公司介绍,童年时光ChildLife所处行业的品牌地位及优势。
咨询